scPharmaceuticals Inc. (NASDAQ: SCPH) had its price target lowered by analysts at Maxim Group from $20.00 to $12.00. They now have a "buy" rating on the stock.
scPharmaceuticals Inc. (NASDAQ: SCPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease